A review of flash glucose monitoring in type 2 diabetes
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Continuous glucose monitoring systems are increasingly being adopted as an alternative to self-monitoring of blood glucose (SMBG) by persons with diabetes mellitus receiving insulin therapy. Main body: The FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, United Kingdom) consists of a factory-calibrated sensor worn on the back of the arm which measures glucose levels in the interstitial fluid every minute and stores the reading automatically every 15 min. Swiping the reader device over the sensor retrieves stored data and displays current interstitial glucose levels, a glucose trend arrow, and a graph of glucose readings over the preceding 8 h. In patients with type 2 diabetes (T2D) receiving insulin therapy, pivotal efficacy data were provided by the 6-month REPLACE randomized controlled trial (RCT) and 6-month extension study. Compared to SMBG, the flash system significantly reduced the time spent in hypoglycemia and frequency of hypoglycemic events, although no significant change was observed in glycosylated hemoglobin (HbA1c) levels. Subsequent RCTs and real-world chart review studies have since shown that flash glucose monitoring significantly reduces HbA1c from baseline. Real-world studies in both type 1 diabetes or T2D populations also showed that flash glucose monitoring improved glycemic control. Higher (versus lower) scanning frequency was associated with significantly greater reductions in HbA1c and significant improvements in other measures such as time spent in hypoglycemia, time spent in hyperglycemia, and time in range. Additional benefits associated with flash glucose monitoring versus SMBG include reductions in acute diabetes events, all-cause hospitalizations and hospitalized ketoacidosis episodes; improved well-being and decreased disease burden; and greater treatment satisfaction. Conclusion: T2D patients who use flash glucose monitoring might expect to achieve significant improvement in HbA1c and glycemic parameters and several associated benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623 · cited 2×
“Evidence interpretation The reasons for discordance between the REPLACE trial [8] and subsequent RCTs [10, 11] and real-world studies [12–14] with respect to the effects of flash glucose monitoring on HbA1c are unknown, although the”
MethodDunn, T. C., Xu, Y., Hayter, G., & Ajjan, R. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.015 · Cited by 239
Evans, M., Welsh, Z., Ells, S., & Seibold, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00720-0 · Cited by 185
Fokkert, M., van Dijk, P., Edens, M., Barents, E., Mollema, J., Slingerland, R., Gans, R., & Bilo, H. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000809 · Cited by 163
Wright, E. E., Kerr, M. S. D., Reyes, I. J., Nabutovsky, Y., & Miller, E. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0069 · Cited by 115 · cited 1×
“A real-world retrospective, observational study which analyzed data from the US electronic health record database IBM Explorys showed that de novo use of flash glucose monitoring significantly reduced HbA1c in T2D patients (n = 1084) not using bolus insulin [13].”
Kröger, J., Fasching, P., & Hanaire, H. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00741-9 · Cited by 90
Polonsky, W. H., Fisher, L., Schikman, C. H., Hinnen, D. A., Parkin, C. G., Jelsovsky, Z., Axel-Schweitzer, M., Petersen, B., & Wagner, R. S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0073 · Cited by 85
Ajjan, R. A., Jackson, N., & Thomson, S. A. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119827456 · Cited by 79
Furler, J., O'Neal, D., Speight, J., Blackberry, I., Manski-Nankervis, J.-A., Thuraisingam, S., de La Rue, K., Ginnivan, L., Doyle, R., Holmes-Truscott, E., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30385-7 · Cited by 55
Cited by
Uhl, S., Choure, A., Rouse, B., Loblack, A., & Reaven, P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad652 · Cited by 76
Li, M., Liu, Z., Yang, X., Zhang, J., Han, M., Zhang, Y., & Liu, Y. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108632 · Cited by 14
Al Hayek, A. A., & Al Dawish, M. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02508-y · Cited by 9
The Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Dabbagh, Z., McKee, M. D., Pirraglia, P. A., Clements, K. M., Liu, F., Amante, D. J., Shukla, P., & Gerber, B. S. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0536 · Cited by 7
Metadata
- Authors
- Krakauer, M., Botero, J. F., Lavalle-González, F. J., Proietti, A., & Barbieri, D. E.
- Venue
- Diabetology & Metabolic Syndrome
- Published
- 2021-04-09
- Volume
- 13
- Issue
- 1
- Pages
- 42-42
- ISSN
- 1758-5996 (ISSN-L)
- OpenAlex
- W3145524033
- Cited by
- 71
- References
- 11
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of flash glucose monitoring in type 2 diabetes. https://app.cochat.ai/papers/10.1186/s13098-021-00654-3
- The paper
- Krakauer, M., Botero, J. F., Lavalle-González, F. J., Proietti, A., & Barbieri, D. E. (2021). A review of flash glucose monitoring in type 2 diabetes. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-021-00654-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.